Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2025 08:42 ET | Source: Ipsen Pharma

Ipsen présentera, lors de deux sessions « late-breaking » au congrès de l’AASLD, de nouvelles données sur la CBP confirmant l’efficacité et la tolérance à long terme d’IQIRVO® ainsi que de nouvelles analyses sur les mécanismes sous-jacents

Les données intermédiaires de l’étude d’extension ouverte à long terme ELATIVE évaluant IQIRVO® (élafibranor) démontrent une réponse biochimique soutenue, une stabilisation des marqueurs de fibrose et...
November 07, 2025 08:42 ET | Source: Ipsen Pharma

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

Interim data from the IQIRVO® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in...
November 07, 2025 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif.,...
November 07, 2025 08:00 ET | Source: Rivus Pharmaceuticals, Inc.

Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025

Phase 2 M-ACCEL trial in MASH met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups
November 15, 2024 16:00 ET | Source: INVENTIVA

Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec empagliflozine chez des patients atteints de MASH et DT2

Les résultats seront présentés lundi 18 novembre par poster lors de la session « late-breaker » du congrès de l’AASLD The Liver Meeting® à San Diego.L'étude LEGEND a atteint son critère principal...
November 15, 2024 16:00 ET | Source: INVENTIVA

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its...
November 15, 2024 11:02 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
November 15, 2024 11:02 ET | Source: Arbutus Biopharma Corporation

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...
November 15, 2024 11:01 ET | Source: Barinthus Biotherapeutics

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with
November 15, 2024 11:01 ET | Source: Arbutus Biopharma Corporation

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of...